Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery

Purpose: to study the effectiveness of aflibercept in the treatment of neovascular age-related macular degeneration (AMD) combined with cataract phacoemulsification with intraocular lens (IOL) implantation. Material and methods. A short-term, prospective, controlled, non randomized comparative study...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Kuznetsov, E. V. Tur, A. V. Zurochka, V. S. Rykun
Format:	Article
Language:	Russian
Published:	Real Time Ltd 2018-10-01
Series:	Российский офтальмологический журнал
Subjects:	афлиберцепт возрастная макулярная дегенерация анти-vegf терапия мультиплексный анализ aflibercept age-related macular degeneration anti-vegf therapy multiplex analysis
Online Access:	https://roj.igb.ru/jour/article/view/119
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION
by: N. A. Bakunina, et al.
Published: (2018-10-01)

The Effectiveness of Retinalamin® Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of Age- Related Macular Degeneration
by: V. V. Neroev, et al.
Published: (2018-10-01)

Aflibercept for the therapy of retinal diseases. A review of clinical studies
by: T. D. Okhotsimskaya, et al.
Published: (2018-10-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01)

Analysis of Clinical Study Results Obtained in Patients with Neovascular Age-Related Macular Degeneration in 2005–2020. Review
by: N. A. Gavrilova, et al.
Published: (2022-04-01)

THE FIRST EXPERIENCE OF USING ANTI-VEGF THERAPY PRIOR TO CATARACT SURGERY IN PATIENTS WITH DIABETIC MACULAR EDEMA
by: N. A. Malysheva
Published: (2018-10-01)

Clinical effectiveness of nutrof total supplement for Dry age-related macular Degeneration
by: E. N. Eskina, et al.
Published: (2018-10-01)

Evaluation of Flowmetry Indicators in Patients with a Wet AMD Form during Antiangiogenic Therapy
by: N. Yu. Yousef, et al.
Published: (2019-12-01)

A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01)

Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment
by: L. A. Golota, et al.
Published: (2025-03-01)

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
by: Bhagya Weerasinghe, et al.
Published: (2021-01-01)

The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study
by: V. V. Neroev, et al.
Published: (2023-12-01)

THE ROLE OF VASCULAR GROWTH FACTORS IN DIABETIC RETINOPATHY AND MACULAR EDEMA DEVELOPMENT
by: A. G. Iskhakova, et al.
Published: (2018-10-01)

Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration
by: Masaaki Saito, et al.
Published: (2025-08-01)

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
by: S. V. Nedogoda, et al.
Published: (2020-03-01)

Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity
by: A. N. Kulikov, et al.
Published: (2025-03-01)

Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
by: A. B. Galimova, et al.
Published: (2023-12-01)

Use of Bevacizumab in the Treatment of Corneal Neovascularization
by: Tuba Çelik, et al.
Published: (2015-01-01)

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials
by: Usha Chakravarthy, FRCOphth, PhD, et al.
Published: (2025-09-01)

Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study Author List
by: Lorenz K, et al.
Published: (2025-08-01)

Structural and Functional Criteria of Neuroprotection Effectiveness after Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration
by: N. S. Zhajvoronok, et al.
Published: (2019-12-01)

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study
by: Masayuki Ohnaka, et al.
Published: (2025-05-01)

Automated fluid monitoring to optimize the follow-up of neovascular age-related macular degeneration patients in the Brazilian population
by: Virginia Mares, et al.
Published: (2025-07-01)

Efficiency of surgical treatment of neovascular glaucoma: a retrospective analysis
by: A. V. Zolotarev, et al.
Published: (2023-07-01)

Pharmacological Analysis of Resistance to Anti-VEGF Therapy
by: M. V. Budzinskaya, et al.
Published: (2019-01-01)

Expression of endothelin in experimental myocardial infarction in a changed concentration of FGF and VEGF
by: M. G. Shurygin, et al.
Published: (2013-02-01)

Efficacy and prognostic factors of anti-VEGF treatment for neovascular age-related macular degeneration: An OCTA imaging-based deep learning analysis
by: Shengnan Liu, et al.
Published: (2025-10-01)

Early Anatomical and Functional Outcomes of Faricimab in Recalcitrant Neovascular Age-Related Macular Degeneration: A Retrospective Real-World Study in an East-Asian Population
by: Yen-An Lai, et al.
Published: (2025-06-01)

Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients
by: Xu Yufeng, et al.
Published: (2025-07-01)

New Qualitative Methods for Assessing the “Fluid” in the Retina in Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2021-07-01)

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy
by: Wael Ahmed Ewais, et al.
Published: (2025-06-01)

Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis
by: Ali Khodor, et al.
Published: (2025-07-01)

Impact of low-molecular-weight heparins on survival of cancer patients
by: V. V. Ptushkin
Published: (2022-11-01)

Metabolomics analysis uncovers metabolic changes and remodeling of anti-VEGF therapy on macular edema
by: Congcong Yan, et al.
Published: (2025-07-01)

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema
by: Viktoria Deiters, et al.
Published: (2025-05-01)

Optical Coherent Tomography-Angiography in the Research of Myopia Complicated by Choroidal Neovascularization
by: E. A. Drozdova, et al.
Published: (2020-09-01)

Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment
by: V. G. Likhvantseva, et al.
Published: (2022-10-01)

Evaluation of the Effectiveness of VEGF Effect on the Regeneration of the Anterior Tracheal Surface in the Early Postoperative Period
by: I. S. Kurganskiy, et al.
Published: (2021-01-01)

Plasma levels of the lymphangiogenic factors VEGF-C, VEGF-D, and CXCL-12 are elevated in advanced diabetic nephropathy
by: Qingshan Tian, et al.
Published: (2025-12-01)